EUVIMEDEUVIMED entdecken
Crossref

Postnatal genetic testing on cord blood for prenatally identified high‐probability cases

Sophie Adams iD, Hannah Llorin iD, Lori J Dobson, Courtney Studwell iD, Louise Wilkins-Haug iD, Stephanie Guseh iD, Kathryn J Gray iD

Prenatal Diagnosis · 2023

DOI: 10.1002/pd.6352 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Prenatal Diagnosis, 2023. Verfasst von Sophie Adams und 6 weiteren Autor:innen. Beteiligte Einrichtung: Center for Fetal Medicine and Reproductive Genetics, Department of Obstetrics and Gynecology, Brigham and Women's Hospital, Boston, Massachusetts, US…. Hauptthemen laut MEDLINE: Fetal Blood, Cell-Free Nucleic Acids. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 36 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To evaluate the utility of postnatal genetic testing on umbilical cord blood (CB) for prenatally identified high‐probability fetuses.

Method

CB for genetic testing was offered to individuals who met one of the following criteria: (i) fetal anomaly, (ii) positive non‐invasive prenatal screening by cfDNA or biochemical analysis, or (iii) family history. Individuals with diagnostic testing, but not microarray, were also included when recommended by society guidelines. CB was collected at Brigham and Women's and Emerson Hospitals between 2016 and 2021.

Results

448 individuals consented for cord blood testing (370 (82.6%) for fetal anomalies, 51 (11.4%) for high‐probability cfDNA, and 27 (6.0%) for family history) and a total of 393 (87.7%) samples were analyzed. Genetic testing yielded a diagnosis in 92 (23.4%) neonates by karyotype ( n = 37), chromosomal microarray (CMA) ( n = 32), and other molecular analysis ( n = 23). Testing averaged 10.3 days (range 1–118 days). 68 (73.9%) diagnoses potentially impacted neonatal management. MCC could not be definitively excluded in only 1.4% (6/418) of samples.

Conclusion

Prenatal identification of high‐probability fetuses and genetic testing on CB facilitates timely genetic diagnoses and neonatal management. Testing provides reassurance and reduces a postnatal diagnostic odyssey for high‐probability neonates.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fetal BloodCell-Free Nucleic AcidsInfant, NewbornPregnancyHumansFemaleGenetic TestingFetusProbability

Substanzen

Cell-Free Nucleic Acids

Autor:innen und Institutionen

  • Center for Fetal Medicine and Reproductive Genetics, Department of Obstetrics and Gynecology, Brigham and Women's Hospital, Boston, Massachusetts, USA.
  • Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA.
  • Division of Maternal-Fetal Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

ORCID-Profile: Sophie Adams, Hannah Llorin, Courtney Studwell, Louise Wilkins-Haug, Stephanie Guseh, Kathryn J Gray

Zitieren

APA

Adams, S., Llorin, H., Dobson, L. J., Studwell, C., Wilkins-Haug, L., Guseh, S., & Gray, K. J. (2023). Postnatal genetic testing on cord blood for prenatally identified high‐probability cases. Prenatal Diagnosis. https://doi.org/10.1002/pd.6352

Vancouver

Adams S, Llorin H, Dobson LJ, Studwell C, Wilkins-Haug L, Guseh S, et al. Postnatal genetic testing on cord blood for prenatally identified high‐probability cases. Prenatal Diagnosis. 2023. doi:10.1002/pd.6352

BibTeX
@article{Adams2023,
  author = {Adams, Sophie and Llorin, Hannah and Dobson, Lori J and Studwell, Courtney and Wilkins-Haug, Louise and Guseh, Stephanie and Gray, Kathryn J},
  title = {Postnatal genetic testing on cord blood for prenatally identified high‐probability cases},
  journal = {Prenatal Diagnosis},
  year = {2023},
  doi = {10.1002/pd.6352}
}
Kostenlos starten →